Received Aug 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Unrelated to the Shingrix dose the patient developed COVID in December 2020.; The first dose make him feel unwell; high fever for about 3 days.; This non-serious case was reported by a other health professional via sales rep and described the occurrence of feeling unwell in a 55-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included prostatic disorder. In SEP-2020, the patient received the 1st dose of Shingrix. In DEC-2020, between 2 and 4 months after receiving Shingrix, the patient experienced covid-19 (Verbatim: Unrelated to the Shingrix dose the patient developed COVID in December 2020.). On an unknown date, the patient experienced feeling unwell (Verbatim: The first dose make him feel unwell) and fever (Verbatim: high fever for about 3 days.). The outcome of the feeling unwell and fever were resolved (duration 3 days) and the outcome of the covid-19 was not reported. The reporter considered the feeling unwell and fever to be related to Shingrix. The reporter considered the covid-19 to be unrelated to Shingrix. The company considered the feeling unwell and fever to be related to Shingrix. The company considered the covid-19 to be unrelated to Shingrix. Linked case(s) involving the same patient: US2025AMR108260 Additional Information: GSK Receipt Date: 20-AUG-2025 Patient took dose 1 of Shingrix in September of 2020. The first dose make him feel unwell with a high fever for about 3 days. Unrelated to the Shingrix dose the patient developed COVID in December 2020.; Sender's Comments: GSK-US2025AMR108260:
Prostatic disorder